_edited.png)
GLP-1 Medications and Eye Health: What Patients Should Know Before Starting Ozempic, Wegovy, Mounjaro, or Zepbound
- Christopher Wolfe, OD, FAAO, Dipl. ABO
- Jun 2
- 8 min read
GLP-1 medications like Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Victoza, and Saxenda are helping many people manage type 2 diabetes, weight, and cardiovascular risk. But for some patients, especially those with diabetes, diabetic retinopathy, age-related macular degeneration, or certain optic nerve risk factors, these medications may require closer eye health monitoring.
The American Optometric Association recommends that patients starting a GLP-1 medication have an in-person, comprehensive, dilated eye exam either within the 12 months before starting treatment or within one month after starting. At Exclusively Eyecare, Dr. Behrendt, Dr. Morris, and Dr. Wolfe can help evaluate your retina, optic nerve, and overall eye health before or soon after beginning GLP-1 therapy.
What Are GLP-1 Medications?
GLP-1 receptor agonists, often called GLP-1s, are medications that help the body regulate blood sugar, appetite, and digestion. They were first developed for people with type 2 diabetes, but some are now also used for weight management and cardiovascular risk reduction.
Common GLP-1 and related medications include:
Generic Name | Brand Names |
Semaglutide | Ozempic, Wegovy, Rybelsus |
Tirzepatide | Mounjaro, Zepbound |
Dulaglutide | Trulicity |
Liraglutide | Victoza, Saxenda |
Exenatide | Byetta, Bydureon BCise |
Lixisenatide | Adlyxin |
These medications may help by increasing insulin release when blood sugar is high, reducing glucagon release after meals, slowing stomach emptying, increasing fullness, improving blood sugar control, and supporting weight loss.
Why Is Exclusively Eyecare Talking About GLP-1 Medications and eye health?
GLP-1 medications can provide major health benefits, but the AOA report highlights several possible eye-related concerns that patients should understand. These risks are not a reason to panic or stop medication on your own. Instead, they are a reason to make sure your eye health is being monitored.
At Exclusively Eyecare, Dr. Behrendt, Dr. Morris, and Dr. Wolfe want patients to understand the main eye concerns discussed in the AOA report, including:
Diabetic retinopathy progression
Sudden vision changes
A rare optic nerve condition called NAION
Possible increased risk of neovascular age-related macular degeneration
Rare reports of other eye problems, such as uveitis, optic neuropathy, or double vision
GLP-1s and Diabetic Retinopathy
If you have diabetes, one of the most important reasons to schedule an exam at Exclusively Eyecare before or soon after starting a GLP-1 medication is to check for diabetic retinopathy.
Diabetic retinopathy happens when diabetes damages the tiny blood vessels in the retina, the light-sensitive tissue at the back of the eye. In some people, rapid improvement in blood sugar can temporarily worsen diabetic retinopathy, especially if retinopathy is already present.
The AOA report notes that in the SUSTAIN-6 trial, diabetic retinopathy complications occurred in 3.0% of patients using semaglutide compared with 1.8% of patients using placebo. The report explains that this may be related to rapid HbA1c reduction, which is already known to sometimes contribute to early worsening of retinopathy.
Patients who may need closer follow-up with Dr. Behrendt, Dr. Morris, or Dr. Wolfe include those with:
Existing diabetic retinopathy
More advanced diabetic eye disease
A high starting HbA1c
Rapid improvement in blood sugar after beginning treatment
Can GLP-1 Medications Cause Blurry Vision?
Some patients may notice blurry or fluctuating vision after starting a GLP-1 medication. This does not always mean permanent damage is happening.
Vision can change when blood sugar levels shift quickly. Rapid changes in glucose can affect the lens inside the eye, leading to temporary changes in focusing. Patients may notice:
Blurry vision
Fluctuating vision
Changes in glasses or contact lens prescription
Distorted central vision
A dark or missing spot in central vision
Any new vision symptom should be evaluated promptly at Exclusively Eyecare, especially if you have diabetes or a history of diabetic eye disease.
What Is NAION?
The AOA report also discusses a rare but serious optic nerve condition called non-arteritic anterior ischemic optic neuropathy, or NAION.
NAION happens when blood flow to the optic nerve is reduced. The optic nerve carries visual information from the eye to the brain. When the optic nerve is affected, vision loss can occur suddenly.
Common signs of NAION include:
Sudden, painless vision loss in one eye
Blurred vision
A missing area in the visual field, often above or below center
New difficulty seeing colors
Optic nerve swelling seen during an eye exam
Risk factors for NAION include:
Diabetes
High blood pressure
High cholesterol
Obstructive sleep apnea
A crowded optic nerve, sometimes called a “disc at risk”
Optic nerve head drusen
According to the AOA report, the European Medicines Agency concluded in June 2025 that NAION is a very rare side effect of semaglutide, estimated at up to 1 in 10,000 patients. The report also states that large epidemiologic studies estimate semaglutide use is associated with a roughly two-fold increased risk, corresponding to about one additional case per 10,000 person-years.
Because NAION involves the optic nerve, a comprehensive dilated eye exam at Exclusively Eyecare can help Dr. Behrendt, Dr. Morris, and Dr. Wolfe identify optic nerve features that may be important to monitor.
Should You Stop Taking Ozempic, Wegovy, or Another GLP-1 If Your Vision Changes?
Do not stop or change a prescribed medication without talking to the clinician who prescribed it.
However, the AOA report states that patients should seek immediate care for sudden or worsening vision changes. If NAION is confirmed, the report recommends that GLP-1 treatment should be discontinued and the patient’s broader health care team should be consulted immediately.
Contact Exclusively Eyecare promptly if you experience:
Sudden vision loss
Sudden blurry vision in one eye
A curtain, shadow, or missing area in vision
New distortion in central vision
New double vision
New eye pain or light sensitivity
Sudden changes in color vision
GLP-1s and Macular Degeneration
The AOA report also highlights an emerging concern related to neovascular age-related macular degeneration, also called wet AMD.
One population-based study discussed in the report found that the risk of developing neovascular AMD was 0.2% in GLP-1RA users compared with 0.1% in non-users. Although the absolute risk was low, the relative risk was more than two times higher among GLP-1 users.
This does not mean every patient on a GLP-1 medication will develop AMD. It does mean that patients with existing AMD or AMD risk factors should be monitored carefully.
If you have macular degeneration or have been told you are at risk for AMD, Dr. Behrendt, Dr. Morris, and Dr. Wolfe at Exclusively Eyecare can help determine an appropriate monitoring schedule.
Who Should Have an Eye Exam Before Starting a GLP-1?
The AOA report recommends a baseline dilated eye exam for patients starting GLP-1 therapy, especially those with diabetes or any form of age-related macular degeneration.
You should be especially proactive about scheduling an exam at Exclusively Eyecare if you:
Have type 2 diabetes
Have diabetic retinopathy
Have age-related macular degeneration
Have high blood pressure
Have high cholesterol
Have sleep apnea
Have been told you have a crowded optic nerve or “disc at risk”
Have optic nerve head drusen
Have a history of sudden vision loss
Are experiencing blurry, fluctuating, distorted, or missing vision
What Kind of Eye Exam Do You Need?
A quick vision screening is not enough.
The AOA report recommends an in-person, comprehensive, dilated eye examination. During this visit at Exclusively Eyecare, Dr. Behrendt, Dr. Morris, or Dr. Wolfe may evaluate:
Visual acuity
Eye pressure
Retina health
Optic nerve appearance
Signs of diabetic retinopathy
Signs of macular degeneration
Signs of optic nerve swelling or crowding
Changes in glasses or contact lens prescription
For higher-risk patients, the report also notes that fundus photography and possibly OCT imaging may be useful for documentation and monitoring.
When Should You Schedule an Eye Exam?
According to the AOA report, patients starting a GLP-1 medication should have a comprehensive dilated eye exam:
Within 12 months before starting the medication, or
Within one month after starting the medication
Patients at higher risk may need closer follow-up during the first 12 to 18 months after starting therapy.
At Exclusively Eyecare, Dr. Behrendt, Dr. Morris, and Dr. Wolfe can recommend a personalized follow-up schedule based on your retina, optic nerve, diabetes status, age, medication history, and overall health.
Are GLP-1 Medications Bad for Your Eyes?
Not necessarily.
GLP-1 medications can have meaningful benefits for blood sugar control, weight management, cardiovascular health, and kidney protection in appropriate patients. The key message is not that GLP-1s are “bad” for your eyes. The key message is that some patients need better eye monitoring before and after starting them.
For many patients, GLP-1 treatment may be part of a larger plan to improve long-term health. Exclusively Eyecare’s role is to help protect your vision while your medical team manages your systemic health.
What Patients Should Tell Exclusively Eyecare
At your next visit with Dr. Behrendt, Dr. Morris, or Dr. Wolfe, tell us if you are taking or planning to take:
Ozempic
Wegovy
Rybelsus
Mounjaro
Zepbound
Trulicity
Victoza
Saxenda
Byetta
Bydureon BCise
Adlyxin
Any compounded or weight-loss injection marketed as semaglutide or tirzepatide
Also share whether you have diabetes, recent HbA1c changes, high blood pressure, high cholesterol, sleep apnea, kidney disease, thyroid disease, or a history of pancreatitis or gallbladder disease.
This information helps Exclusively Eyecare better understand your risk factors and monitor your eyes appropriately.
Bottom Line: Protect Your Vision While Improving Your Health
GLP-1 medications are transforming care for many people with diabetes, obesity, and cardiovascular risk. But because these medications may be associated with rare or temporary eye-related complications, patients should take a proactive approach to vision care.
Before or shortly after starting a GLP-1 medication, schedule a comprehensive dilated eye exam at Exclusively Eyecare. This gives Dr. Behrendt, Dr. Morris, and Dr. Wolfe a baseline view of your retina and optic nerve, helps identify risk factors early, and allows our team to monitor changes over time.
If you experience sudden or worsening vision changes while taking a GLP-1 medication, contact Exclusively Eyecare immediately.
FAQ:
GLP-1 Medications and Eye Health
Can Ozempic or Wegovy affect your eyes?
They may. The AOA report discusses potential eye concerns related to GLP-1 medications, including diabetic retinopathy progression, blurry vision related to rapid blood sugar changes, rare optic nerve events such as NAION, and possible AMD-related concerns.
Do I need an eye exam before starting a GLP-1?
Yes. The AOA recommends an in-person, comprehensive, dilated eye exam within 12 months before starting a GLP-1 medication or within one month after starting. Exclusively Eyecare can provide this baseline evaluation and help monitor for changes over time.
Why can blood sugar improvement affect vision?
When blood sugar changes quickly, the lens inside the eye can temporarily change shape or focusing ability. In patients with diabetic retinopathy, rapid HbA1c improvement may also temporarily worsen retinal disease.
What vision symptoms are urgent?
Sudden vision loss, new blurry vision in one eye, missing areas of vision, distorted central vision, new double vision, or sudden color vision changes should be evaluated immediately. Contact Exclusively Eyecare right away if these symptoms occur.
Should I stop my GLP-1 medication if I have blurry vision?
Do not stop a prescribed medication without speaking with your prescribing clinician. However, contact Exclusively Eyecare promptly for new or worsening vision symptoms. If NAION is confirmed, the AOA report recommends discontinuing GLP-1 therapy in coordination with the patient’s health care team.
Are people with diabetes at higher risk?
People with diabetes are already at risk for diabetic eye disease. Patients with existing diabetic retinopathy, high HbA1c, or rapid blood sugar improvement may need closer monitoring with Dr. Behrendt, Dr. Morris, or Dr. Wolfe after starting a GLP-1.
Can GLP-1s cause permanent vision loss?
Serious events appear rare, but conditions such as NAION or advanced diabetic retinopathy can threaten vision. That is why baseline and follow-up eye exams at Exclusively Eyecare are important.
Comments